Breaking: Vertex makes $10B deal for commercial endocrinology biotech Crinetics - Endpoints News
Source:Endpoints.news
Vertex Pharmaceuticals acquires Crinetics Pharmaceuticals for $10B ($85/share), gaining acromegaly drug Palsonify and endocrinology pipeline with ~$5B peak sales potential.